Navigation Links
Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) In A Phase 2 Study Resulted In High Rates Of Colonization And Statistically Significant Reductions In Recurrence Of C. difficile Infection
Date:4/22/2013

sceptible individuals with a non-toxin-producing strain of C. difficile appears to prevent infection by a toxic, virulent strain and these data support that observation. The results of the study provide insight into how colonization rates may be increased further, for example, by starting VP20621 dosing earlier and using the optimum dosing regimen in confirmatory studies powered to show a difference in recurrence rates. These are very exciting data, and offer clinicians and patients hope that a preventive therapy for recurrent CDI may one day be available to them."

About the Phase 2 study
The Phase 2 randomized, double-blind study was designed to determine the tolerability of VP20621 dosed orally for up to 14 days in adults previously treated for CDI with oral vancomycin or metronidazole. After completing the antibiotic treatment, subjects were given either placebo (n=43), or VP20621 doses of 104 spores QD (once per day) for 7 days (n=41), 107 spores QD for 7 days (n=43), or 107 spores QD for 14 days (n=41).  The overall median age of study subjects was 59 years; 39 percent were >/= 65 years old; 62 percent were female. Data from the study are shown below: 

Microbiology and Clinical endpoints:
Study drug was to be administered to all subjects for 14 days to maintain the blind.  Data below pertain to the 6 weeks following the first dose of study drug, which defined the period for evaluation of CDI recurrence. Colonization was determined by microbiological culture of stool and CDI recurrence was defined as >/= 3 unformed stools within 24 hours, positive C. difficile stool assay and no other likely cause of diarrhea occurring after day one through week 6.

Detection of NTCD in stool and rates of CDI recurrence, Antibacterial Use for CDI Treatment and Clinical Diarrhea Events; Placebo vs. VP20621Placebo

VP20621104 x 7d

107 x 7d


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. ... tissue protection, repair and regeneration, today announced that ... scheduled to present a corporate overview at two upcoming ... at the SeeThruEquity 4 th Annual Microcap Conference ... York City at 11:00 am EDT.  A ...
(Date:5/22/2015)... and KING OF PRUSSIA, Pa. , May ... has awarded CSL Behring its 2015 Corporate Leadership ... to advancing science and improving the care of the bleeding ... , CEO and Managing Director, CSL Limited, during the NHF ... on May 21. "The National Hemophilia Foundation ...
(Date:5/22/2015)... WASHINGTON , May 22, 2015  The ... certain diagnosed victims of mesothelioma get the best ... making certain individuals with this rare cancer caused ... the most up-to-date information related to treatment options ... information please call the Mesothelioma Victims Center anytime ...
Breaking Medicine Technology:RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
... on the Menopause show significant, improvement in vaginal ... ... ARBOR, Mich., May 21 QuatRx Pharmaceuticals today,announced further ... Ophena(TM),(ospemifene tablets) to treat postmenopausal women with symptoms of,vulvovaginal ...
... Mass., May 21 Pressure,BioSciences, Inc. (Nasdaq: ... New York University (NYU) School of Medicine, the ... Health made presentations,highlighting the advantages of the Company,s ... meetings earlier this week.,There were three oral presentations ...
Cached Medicine Technology:QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy 2QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy 3Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 2Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 3Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 4
(Date:5/22/2015)... York, NY (PRWEB) May 22, 2015 ... Multifamily Housing, Marc Zuluaga, has been selected by Consulting-Specifying ... engineering. The award winners are featured in the May/June ... to 40 building industry professionals age 40 and younger ... the building community, as well as in other areas ...
(Date:5/22/2015)... A new program for the "In America" television ... Physical Therapy. , James Earl Jones will host ... physical therapy and discusses how the exercises can decrease ... of ailments and injuries. Physical therapists work with ... enhances daily activities such as house cleaning and shopping, ...
(Date:5/22/2015)... In efforts to offer full and ... particular muscles stretches has been a large focus over ... now complete, Chunk Fitness envisions a mid-June launch of ... and released at a later point in time. The ... http://www.chunkfitness.com/stretches . , About the Company: Chunk Fitness was ...
(Date:5/22/2015)... Aliso Viejo, CA (PRWEB) May 22, 2015 ... 30 editable lower thirds designed exclusively for Final Cut ... creatively compatible with any design. , Intuitive on-screen-controls ... each unique lower third. Reflections, colors, layouts, and much ... the Inspector window. , Pro3rd Impression ...
(Date:5/21/2015)... California (PRWEB) May 21, 2015 Her popular ... at the Hilton Hotel in San Gabriel on Saturday, May ... and over again from men and women who are unhappy ... the right partner." , "Many singles think that their biggest ... The seeker would go from one relationship to another trying ...
Breaking Medicine News(10 mins):Health News:Steven Winter Associates’ Marc Zuluaga Earns Innovative Engineering Award 2Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2Health News:Bestselling Author Sheds Light on Why Modern Dating is Hurting People's Chances of Finding a Lasting Relationship 2
... Cell phone distractions account for more than 300,000 car crashes each ... to limit or prohibit the use of things like cell phones ... University finds a widening gap between the evidence on distracted driving ... new study, published this month in the American Journal of ...
... -- Patients with bipolar disorder may be eligible ... medications -- quetiapine (Seroquel), a widely prescribed second-generation ... stabilizer. NewYork-Presbyterian Hospital/Weill Cornell Medical Center is ... only site in the greater New York metropolitan ...
... By Steven Reinberg HealthDay Reporter , ... recommend antibiotics for asthma, almost 1 million children with ... in the United States, a new study finds. ... this suggests that we as pediatricians are prescribing them ...
... of tuberculosisas well as in the practices, programs and ... human immunodeficiency virus (HIV)the spread of multidrug-resistant (MDR) tuberculosis ... Research in the June issue of The Journal ... of 18F-FDG positron emission tomography (PET) scans can help ...
... immobilise radioactive forms of iodine using a microwave, has been ... Iodine radioisotopes are produced by fission of uranium fuel in ... it is highly mobile in the environment and selective uptake ... following long term exposure. Furthermore, iodine-129, which is a type ...
... , MONDAY, May 23 (HealthDay News) -- Are you the type ... theater? If so, here,s some good news: A new Norwegian study ... in better health than those who don,t. Both men and ... health and satisfaction with life than those who were less engaged. ...
Cached Medicine News:Health News:Temple-led study finds widening gap between distracted driving and legislation 2Health News:New study aims to improve long-term treatment for patients with bipolar disorder 2Health News:Too Many Kids Getting Antibiotics for Asthma 2Health News:Too Many Kids Getting Antibiotics for Asthma 3Health News:PET scans predict effectiveness of treatment for multidrug-resistant tuberculosis in HIV patients 2Health News:Expert discovers simple method of dealing with harmful radioactive iodine 2Health News:A Cultured Man Is a Healthier, Happier Man: Study 2Health News:A Cultured Man Is a Healthier, Happier Man: Study 3
These handy dispensers save space and organize gloves in labs and next to hand washers. Clear acrylic. Many other sizes and custom configurations available....
Single side double clamp knife holder for the Vibratome 8000...
... The Professional Gold Package is ... laboratory. The package includes the ... automated system, standard accessory kit, ... specimen mounts 1/2" head, rotating ...
... 1000 Sectioning System provides a versatile means ... plant tissues. The 1000 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effects ...
Medicine Products: